PMC:7212965 / 62231-62730 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T144","span":{"begin":228,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A144","pred":"fma_id","subj":"T144","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T112","span":{"begin":228,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A112","pred":"uberon_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T313","span":{"begin":134,"end":142},"obj":"Disease"},{"id":"T314","span":{"begin":324,"end":332},"obj":"Disease"}],"attributes":[{"id":"A313","pred":"mondo_id","subj":"T313","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A314","pred":"mondo_id","subj":"T314","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T440","span":{"begin":52,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T441","span":{"begin":63,"end":65},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T442","span":{"begin":228,"end":233},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T443","span":{"begin":228,"end":233},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11045","span":{"begin":86,"end":88},"obj":"Chemical"},{"id":"T52126","span":{"begin":381,"end":383},"obj":"Chemical"},{"id":"T97673","span":{"begin":384,"end":387},"obj":"Chemical"},{"id":"T4344","span":{"begin":486,"end":495},"obj":"Chemical"},{"id":"T43028","span":{"begin":497,"end":499},"obj":"Chemical"}],"attributes":[{"id":"A1824","pred":"chebi_id","subj":"T11045","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A37733","pred":"chebi_id","subj":"T52126","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A56678","pred":"chebi_id","subj":"T97673","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A38824","pred":"chebi_id","subj":"T4344","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A63853","pred":"chebi_id","subj":"T43028","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T282","span":{"begin":324,"end":332},"obj":"Phenotype"},{"id":"T283","span":{"begin":346,"end":361},"obj":"Phenotype"},{"id":"T284","span":{"begin":375,"end":379},"obj":"Phenotype"}],"attributes":[{"id":"A282","pred":"hp_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A283","pred":"hp_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A284","pred":"hp_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/HP_0012531"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-sentences","denotations":[{"id":"T467","span":{"begin":0,"end":51},"obj":"Sentence"},{"id":"T468","span":{"begin":52,"end":117},"obj":"Sentence"},{"id":"T469","span":{"begin":118,"end":185},"obj":"Sentence"},{"id":"T470","span":{"begin":186,"end":215},"obj":"Sentence"},{"id":"T471","span":{"begin":216,"end":268},"obj":"Sentence"},{"id":"T472","span":{"begin":269,"end":323},"obj":"Sentence"},{"id":"T473","span":{"begin":324,"end":333},"obj":"Sentence"},{"id":"T474","span":{"begin":334,"end":499},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2365","span":{"begin":134,"end":142},"obj":"Disease"},{"id":"2366","span":{"begin":324,"end":332},"obj":"Disease"},{"id":"2367","span":{"begin":346,"end":352},"obj":"Disease"},{"id":"2368","span":{"begin":353,"end":361},"obj":"Disease"},{"id":"2369","span":{"begin":363,"end":379},"obj":"Disease"}],"attributes":[{"id":"A2365","pred":"tao:has_database_id","subj":"2365","obj":"MESH:C000657245"},{"id":"A2366","pred":"tao:has_database_id","subj":"2366","obj":"MESH:D003967"},{"id":"A2367","pred":"tao:has_database_id","subj":"2367","obj":"MESH:D009325"},{"id":"A2368","pred":"tao:has_database_id","subj":"2368","obj":"MESH:D014839"},{"id":"A2369","pred":"tao:has_database_id","subj":"2369","obj":"MESH:D010146"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Ma, 202049Wuhan Leishenshan Hospital (Wuhan)Dates: 3/5/2020-3/18/2020Last follow-up: NR n = 81Survival: NRInclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs)Age: M 38 y (IQR, 34.5–42.5 y)Sex: 0% femaleGI/liver comorbidities: NRDisease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. Diarrhea: 7.41% (6/81)Nausea/vomiting: NRAbdominal pain: NR AST/ALT - composite report 31/81 abnormal but no thresholdAST M 23 (IQR, 12–453)ALT M 43 (IQR, 13–799)Bilirubin: NR"}